Literature DB >> 15377890

Bicuculline methiodide attenuates hepatic injury and decreases mortality in septic rats: role of cytokines.

Dur-Zong Hsu1, Ming-Yie Liu.   

Abstract

Bicuculline methiodide attenuates inflammation by inhibiting the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, and by increasing the production of the anti-inflammatory cytokine interleukin-10, both of which play important roles in the pathogenesis of sepsis. The aim of this study was to examine the effects of bicuculline methiodide on sepsis in the cecal ligation and puncture septic-rat model. Cytokine production was measured by enzyme-linked immunosorbent assay. Oxidative stress was assessed by determining serum lipid peroxidation and nitrite levels. Hepatic injury was evaluated by determining the levels of serum aspartate aminotransferase, alkaline phosphatase, and total bilirubin. Mortality was recorded within 24 h. Bicuculline methiodide potently decreased the production of tumor necrosis factor-alpha and interleukin-1beta but increased interleukin-10 in serum. Bicuculline methiodide significantly decreased serum lipid peroxidation and nitrite levels. Further, bicuculline methiodide attenuated hepatic injury and reduced mortality after cecal ligation and puncture. Therefore, the alteration of cytokine production may be involved in the effects of bicuculline methiodide on hepatic injury and mortality in septic rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377890     DOI: 10.1097/01.shk.0000136705.33995.bd

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  8 in total

1.  Use of Organ Dysfunction as a Primary Outcome Variable Following Cecal Ligation and Puncture: Recommendations for Future Studies.

Authors:  Mabel N Abraham; Alexander P Kelly; Ariel B Brandwein; Tiago D Fernandes; Daniel E Leisman; Matthew D Taylor; Mariana R Brewer; Christine A Capone; Clifford S Deutschman
Journal:  Shock       Date:  2020-08       Impact factor: 3.454

2.  Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats.

Authors:  Sukru Oter; Mustafa Edremitlioglu; Ahmet Korkmaz; Omer Coskun; Dilek Kilic; Ucler Kisa; Hakan Yaren; Hayati Bilgic
Journal:  Intensive Care Med       Date:  2005-07-21       Impact factor: 17.440

3.  Modeling natural anti-inflammatory compounds by molecular topology.

Authors:  María Galvez-Llompart; Riccardo Zanni; Ramón García-Domenech
Journal:  Int J Mol Sci       Date:  2011-12-20       Impact factor: 5.923

4.  Bicuculline Reduces Neuroinflammation in Hippocampus and Improves Spatial Learning and Anxiety in Hyperammonemic Rats. Role of Glutamate Receptors.

Authors:  Michele Malaguarnera; Marta Llansola; Tiziano Balzano; Belén Gómez-Giménez; Carles Antúnez-Muñoz; Núria Martínez-Alarcón; Rahebeh Mahdinia; Vicente Felipo
Journal:  Front Pharmacol       Date:  2019-02-25       Impact factor: 5.810

Review 5.  Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review.

Authors:  Xiaomin Kang; Linlin Jiang; Yuqing Zhang; Yuehong Zhang; Xuedong An; Liyun Duan; Cunqing Yang; Rongrong Zhou; Yingying Duan; Yuting Sun; Fengmei Lian
Journal:  Chin Med       Date:  2022-02-28       Impact factor: 5.455

6.  Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19.

Authors:  Liang Hong; Min He; Shaoping Li; Jing Zhao
Journal:  Chin Med       Date:  2022-07-07       Impact factor: 4.546

7.  Sesamol ameliorates hypotension by modulating cytokines and PPAR-gamma in systemic inflammatory response.

Authors:  Srinivasan Periasamy; Pei-Yi Chu; Ya-Hui Li; Dur-Zong Hsu; Ming-Yie Liu
Journal:  EXCLI J       Date:  2015-08-13       Impact factor: 4.068

8.  The Dual Role of the GABAA Receptor in Peripheral Inflammation and Neuroinflammation: A Study in Hyperammonemic Rats.

Authors:  Michele Malaguarnera; Tiziano Balzano; Mari Carmen Castro; Marta Llansola; Vicente Felipo
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.